Relevant bibliographies by topics / Co-speakers’ reactions

Contents

  1. Journal articles
  2. Conference papers

Academic literature on the topic 'Co-speakers’ reactions'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Co-speakers’ reactions.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Co-speakers’ reactions"

1

Shima, Midori, Keiji Nogami, Sayaka Nagami, et al. "Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)." Blood 132, Supplement 1 (2018): 1186. http://dx.doi.org/10.1182/blood-2018-99-115792.

Full text
Abstract:
Abstract Introduction: Emicizumab is a novel, subcutaneously injectable, recombinant humanized bispecific monoclonal antibody which mimics the function of activated coagulation factor VIII. Due to its mechanism of action and lack of sequence homology, emicizumab is not expected to induce or be affected by anti-factor VIII (FVIII) antibodies (inhibitors). Emicizumab once-weekly dosing has been approved for hemophilia A patients with inhibitors of all ages in several countries. A clinically meaningful prophylactic effect and favorable safety of emicizumab given every 2 weeks (Q2W) and every 4 we
APA, Harvard, Vancouver, ISO, and other styles
2

Jacoby, Meagan A., Laura E. Finn, Ashkan Emadi, et al. "Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351." Blood 136, Supplement 1 (2020): 19. http://dx.doi.org/10.1182/blood-2020-136880.

Full text
Abstract:
Introduction: CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, has been approved by the US FDA and EMA for the treatment of adults with newly diagnosed, therapy-related AML or AML with myelodysplasia-related changes. The primary endpoint analysis of the pivotal phase 3 study (NCT01696084) that formed the basis for the approvals evaluated older patients with newly diagnosed high-risk/secondary AML; after a median follow-up of 20.7 months, CPX-351 significantly improved medi
APA, Harvard, Vancouver, ISO, and other styles
3

Kawazoe, M., K. Aoki, W. Hirose, et al. "AB1328 LONGITUDINAL SEROLOGICAL STUDY OF ANTI-SARS-CoV-2 SPIKE PROTEIN ANTIBODIES AFTER TWO DOSES OF mRNA VACCINES IN PATIENTS WITH RHEUMATIC DISEASES: ANALYSIS OF EFFECTS OF IMMUNOSUPPRESSANT THERAPY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1893.1–1894. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1217.

Full text
Abstract:
BackgroundThe longitudinal efficacy and safety data of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with rheumatic disease (RD) remains unclear.ObjectivesThe objective of the study was to examine changes over time in anti-SARS-CoV-2 spike protein IgG (anti-S IgG) values in RD patients compared with controls and investigate the effects of immunosuppressants on the values. Safety of vaccine was also evaluated.MethodsRD patients receiving glucocorticoids or immunosuppressants who were scheduled to receive two doses of SARS-CoV-2 mRNA vaccines were incl
APA, Harvard, Vancouver, ISO, and other styles
4

Vaca, Alicia, Nikolaos Ioannou, Mariela Sivina, et al. "Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones." Blood 138, Supplement 1 (2021): 3716. http://dx.doi.org/10.1182/blood-2021-151351.

Full text
Abstract:
Abstract CLL cells proliferate in secondary lymphatic tissues where the CLL cells interact with T cells, monocyte-derived nurselike cells and mesenchymal stromal cells, collectively referred to as the tissue microenvironment. The CLL lymph node morphology with proliferation centers resembles normal B cell follicles, suggesting that mechanisms regulating the expansion of antigen-selected normal B cells during the germinal center (GC) reaction also regulate CLL cell expansion. Normal GC reactions require specialized T follicular helper (Tfh) cells, which provide T cell help to antigen-stimulated
APA, Harvard, Vancouver, ISO, and other styles
5

Eichhorst, Barbara, Carsten Niemann, Arnon P. Kater, et al. "A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial." Blood 138, Supplement 1 (2021): 71. http://dx.doi.org/10.1182/blood-2021-146161.

Full text
Abstract:
Abstract Background: For fit CLL patients (pts), continuous BTK inhibitor treatment is replacing CIT as standard of care in frontline setting, particularly in pts with unfavorable prognostic factors. The time limited combinations venetoclax plus obinutuzumab (GVe) and venetoclax plus rituximab (RVe) have produced high rates of undetectable minimal residual disease (uMRD), which strongly associates with long progression-free survival (PFS) both in frontline and relapsed setting. For frontline therapy GVe is approved in this setting based on data from the CLL14 trial in an unfit population. Howe
APA, Harvard, Vancouver, ISO, and other styles
6

Abe, M., E. Tanaka, E. Inoue, et al. "THU0086 FACTORS ASSOCIATED WITH TREATMENT RESPONSE IN PATIENTS WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS: 3-YEAR OBSERVATION USING THE IORRA COHORT." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 255–56. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3115.

Full text
Abstract:
Background:Patients with elderly-onset rheumatoid arthritis (EORA) are on the rise in the aging or super-aging society, especially in Japan. Patients with EORA have more comorbidities than those with younger-onset RA, a higher risk of adverse drug reactions due to reduced drug metabolism, and a higher risk of infections1). Therefore, patients with EORA tend to receive suboptimal treatment, resulting in insufficient control of disease activity2). Although several studies reported treatment responsiveness in patients with EORA, many of them have a limited observation period3-8), and long-term tr
APA, Harvard, Vancouver, ISO, and other styles
7

Lennon, Paul. "Assessing Short-term Change in Advanced Oral Proficiency." ITL - International Journal of Applied Linguistics 109-110 (January 1, 1995): 75–109. http://dx.doi.org/10.1075/itl.109-110.04len.

Full text
Abstract:
Abstract This paper presents four case studies to demonstrate developments in oral proficiency made by advanced learners of English during two months in England. The data base consists of picture story oral narratives. Performance shortly after arrival in Britain is compared with that at the end of the two months. Assessment was by: subjective reactions of a panel of experienced native-speaker EFL teachers quantitative analysis of transcriptions of recordings. An attempt is made to apply VORSTER’s (1980) components of proficiency developed for use with children mother tongue speakers. The main
APA, Harvard, Vancouver, ISO, and other styles
8

Van Lint, J., N. Jessurun, S. Tas, et al. "POS0289 A CONCEPTUAL FRAMEWORK OF THE COURSE AND TIMEFRAME OF PATIENT-REPORTED ADVERSE DRUG REACTIONS OF BIOLOGICS IN IMMUNE-MEDIATED INFLAMMATORY DISEASES." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 389–90. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1357.

Full text
Abstract:
BackgroundPatients with immune-mediated inflammatory diseases (IMIDs) need chronic drug treatment, including biologics, which may cause adverse drug reactions (ADRs). Information about ADRs is usually restricted to the type of ADRs that may occur with drug use. Common patterns in the course and timeframe of ADRs are often not described while this information may provide valuable insights for patients and healthcare professionals.ObjectivesTo identify common and corresponding items with thematic analysis in the described course of ADRs of biologics reported by patients with IMIDs.MethodsWe used
APA, Harvard, Vancouver, ISO, and other styles
9

Usmani, Saad Z., Maria-Victoria Mateos, Hareth Nahi, et al. "Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update." Blood 134, Supplement_1 (2019): 1865. http://dx.doi.org/10.1182/blood-2019-122765.

Full text
Abstract:
INTRODUCTION: Daratumumab (DARA), a human IgGκ monoclonal antibody targeting CD38, is approved for intravenous (IV; 16 mg/kg) administration as a single agent or in combination with standard-of-care regimens for treatment of multiple myeloma (MM).To improve safety and reduce patient and healthcare provider burden, a subcutaneous (SC) formulation of DARA (1,800 mg co-formulated with recombinant human hyaluronidase PH20 [rHuPH20]; ENHANZE® drug delivery technology, Halozyme, Inc.) was developed. The phase 3, randomized, open-label, non-inferiority COLUMBA study (NCT03277105) evaluated the effica
APA, Harvard, Vancouver, ISO, and other styles
10

Furst, D., E. Keystone, J. Kay, et al. "AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1123–24. http://dx.doi.org/10.1136/annrheumdis-2021-eular.325.

Full text
Abstract:
Background:Therapeutic equivalence of CT-P17 to reference adalimumab (ref-adalimumab) has been shown in patients with moderate-to-severe active rheumatoid arthritis (RA) through primary 24-week results [1]. Here, efficacy, pharmacokinetics (PK), safety and immunogenicity results up to 52-week, including transition data from ref-adalimumab to CT-P17 are presented.Objectives:To evaluate efficacy, PK, safety and immunogenicity when switched from ref-adalimumab to CT-P17 compared to maintaining CT-P17 or ref-adalimumab.Methods:In this study, 648 moderate-to-severe active RA patients despite methot
APA, Harvard, Vancouver, ISO, and other styles
More sources

Conference papers on the topic "Co-speakers’ reactions"

1

Kataoka, Kuniyoshi. "Poetics through Body and Soul: A Plurimodal Approach." In GLOCAL Conference on Asian Linguistic Anthropology 2019. The GLOCAL Unit, SOAS University of London, 2019. http://dx.doi.org/10.47298/cala2019.4-1.

Full text
Abstract:
In this presentation, I will show that various multimodal resources—such as utterance, prosody, rhythm, schematic images, and bodily reactions—may integratively contribute to the holistic achievement of poeticity. By incorporating the ideas from “ethnopoetics” (Hymes 1981, 1996) and “gesture studies” (McNeill 1992, 2005), I will present a plurimodal analysis of naturally occurring interactions by highlighting the interplay among the verbal, nonverbal, and corporeal representations. With those observations, I confirm that poeticity is not a distinctive quality restricted to constructed poetry o
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Co-speakers’ reactions' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography